Dr Lorey Smith
Targeted therapies have revolutionised cancer care, but rarely result in cures. In melanoma, the success of targeted therapies is limited by the persistence of residual disease that undergoes adaptation. I investigate mechanisms underlying drug-induced adaptation using cutting-edge molecular biology techniques to identify ways we can stop this process and prevent drug resistance.
I am also extremely passionate about achieving equity and diversity within the scientific process. Being a member of WiSPP has provided me with the opportunity to meet passionate and inspiring people and make a direct contribution to women in science in the biomedical research community.